Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Neuronal DAMPs exacerbate neurodegeneration via astrocytic RIPK3 signaling
Nydia P. Chang, Evan M. DaPrano, Marissa Lindman, Irving Estevez, Tsui-Wen Chou, Wesley R. Evans, Marialaina Nissenbaum, Micheal McCourt, Diego Alzate, Colm Atkins, Alexander W. Kusnecov, Rafiq Huda, Brian P. Daniels
Nydia P. Chang, Evan M. DaPrano, Marissa Lindman, Irving Estevez, Tsui-Wen Chou, Wesley R. Evans, Marialaina Nissenbaum, Micheal McCourt, Diego Alzate, Colm Atkins, Alexander W. Kusnecov, Rafiq Huda, Brian P. Daniels
View: Text | PDF
Research Article Immunology Neuroscience

Neuronal DAMPs exacerbate neurodegeneration via astrocytic RIPK3 signaling

  • Text
  • PDF
Abstract

Astrocyte activation is a common feature of neurodegenerative diseases. However, the ways in which dying neurons influence the activity of astrocytes is poorly understood. Receptor interacting protein kinase-3 (RIPK3) signaling has recently been described as a key regulator of neuroinflammation, but whether this kinase mediates astrocytic responsiveness to neuronal death has not yet been studied. Here, we used the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson’s disease to show that activation of astrocytic RIPK3 drives dopaminergic cell death and axon damage. Transcriptomic profiling revealed that astrocytic RIPK3 promoted gene expression associated with neuroinflammation and movement disorders, and this coincided with significant engagement of damage-associated molecular pattern signaling. In mechanistic experiments, we showed that factors released from dying neurons signaled through receptor for advanced glycation endproducts to induce astrocytic RIPK3 signaling, which conferred inflammatory and neurotoxic functional activity. These findings highlight a mechanism of neuron-glia crosstalk in which neuronal death perpetuates further neurodegeneration by engaging inflammatory astrocyte activation via RIPK3.

Authors

Nydia P. Chang, Evan M. DaPrano, Marissa Lindman, Irving Estevez, Tsui-Wen Chou, Wesley R. Evans, Marialaina Nissenbaum, Micheal McCourt, Diego Alzate, Colm Atkins, Alexander W. Kusnecov, Rafiq Huda, Brian P. Daniels

×

Figure 2

RIPK3 drives inflammatory transcriptional activation but not proliferation in midbrain astrocytes.

Options: View larger image (or click on image) Download as PowerPoint
RIPK3 drives inflammatory transcriptional activation but not proliferati...
(A and B) IHC analysis of GFAP staining in the SNpc in indicated genotypes 3 days after MPTP treatment (scale bar = 200 μm). (C and D) Flow cytometric analysis of GLAST+ astrocytes in midbrain homogenates derived from indicated genotypes 3 days after MPTP treatment. (E and F) qRT-PCR analysis of indicated genes in midbrain homogenates derived from astrocyte-specific Ripk3 knockouts (E) or astrocyte-specific Ripk3-overexpressing (F) mice 3 days after MPTP treatment. (G and H) Schematic of inducible RIPK3 activation system (G) and stereotactic delivery of dimerization drug into the ventral midbrain (H). (I) qRT-PCR analysis of indicated genes in midbrain homogenates derived from Ripk3-2xFVfl/fl Aldh1l1-Cre+ mice 24 hours following administration of B/B homodimerizer or vehicle control. n = 3–8 mice/group (A and B), 5 mice/group (C and D), 6–9 mice/group (E), 7–8 mice/group (F), 5 mice/group (I). Data are represented as mean values with scatterplots depicting individual biological replicate values. Comparisons via 2-tailed Student’s t test (D) or 2-way ANOVA with Holm-Šídák multiple-comparison test (B, E, F, and I). *P < 0.05, **P < 0.01, ***P < 0.001. G and H were created with Biorender.com.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts